Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — H1 2022 Earnings Presentation
11 slides from Vivoryon Therapeutics's earnings presentation, Sep 30, 2022
Slide 1: Half Year 2022 Results Webcast and Conference Call
HALF YEAR 2022 RESULTS WEBCAST AND CONFERENCE CALL September 30, 2022 |Vivoryon Therapeutics N.V.
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Vivoryon's Approach to Overcoming the Challenges of AD Drug Development
VIVORYON’S APPROACH TO OVERCOMING THE CHALLENGES OF AD DRUG DEVELOPMENT Oral small molecule inhibitor varoglutamstat targeting multiple hallmarks of AD QPCT/L AS KEY TARGET IN AD VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS High unmet medical need in AD despite recent advances CCL2 Abeta First poten
Slide 4: Corporate Development Highlights
CORPORATE DEVELOPMENT HIGHLIGHTS ◆ Financing events to support ongoing clinical development of varoglutamstat ◆ April 2022: EUR 21 million raised in private placement; capital raise supported by a number of high-quality institutional investors from Europe and the U.S. as well as members of Vivoryon’
Slide 5: Clinical Portfolio Highlights
CLINICAL PORTFOLIO HIGHLIGHTS ◆ VIVIAD European Ph 2b study of varoglutamstat completed parallel group, dose-finding part, and independent Data Safety Monitoring Board (DSMB) selected highest dose investigated, 600 mg twice daily (BID), as final dose in second part of study (post-period) ◆ Detailed
Slide 6: Varoglutamstat Clinical Milestones
VAROGLUTAMSTAT CLINICAL MILESTONES 2022/2023 Outlook Phase 2b study in 250 patients with ◆ Clinical Trial Application Phase 2a/b study in 414 patients with early AD MCI/mild AD approved in China Endpoints: safety, attention/working Endpoints: safety, ABC scores/ cognition & EEG , CDR-SB, biomarkers
Slide 7: Clinical Development Strategy
CLINICAL DEVELOPMENT STRATEGY Clear Path To Potential Regulatory Approval Extensive Phase 1 and Phase 2 trials Pivotal study or accelerated approval Phase 2b VIVIAD Assessment of safety, tolerability and FDA Fast Track designation efficacy in 250 Patients MCI and mild AD granted in 2021 Two possible
Slide 8: Condensed Statement of Profit and Loss
CONDENSED STATEMENT OF PROFIT AND LOSS In €k June 30, 2022 June 30, 2021 Research and development expenses (11,067) (9,456) General and administrative expenses (2,311) (2,337) Operating loss (13,378) (11,788) Finance result 844 117 Income taxes (89) 0 Net loss for period (12,583) (11,671) Loss per s
Slide 9: Key Financial Figures
KEY FINANCIAL FIGURES In €k June 30, 2022 December 31, 2021 Cash and cash equivalents 24,383 14,661 Total assets 31,743 24,520 Total equity 25,237 16,557 Shares (number) 22,050,482 20,050,482 In €kh June 30, 2022 June 30, 2021 Cash flows used in operating activities (10,237) (6,072) Cash flows used
Slide 10: Q&A
Q&A
Slide 11: Vivoryon Therapeutics N.V. Contact Details
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany Munich Franz-Josef-Delonge-Str. 5 81249 München Germany info@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — H1 2022 Earnings Presentation on 6ix